| 1 |
Mizumasa T. Diabetes influences peritoneal morphology in uremic patients at the initiation of peritoneal dialysis [J]. Perit Dial Int, 2013, 33(2): 175-181.
|
| 2 |
Qayyum A. Increasing the use of biocompatible, glucose-free peritoneal dialysis solutions [J]. World J Nephrol, 2015, 4(1): 92-97.
|
| 3 |
Lim PS, Chen H-P, Chen C-H, et al. Association between Redox Status of Serum Albumin and Peritoneal Membrane Transport Properties in Patients on Peritoneal Dialysis [J]. Blood Purif, 2015, 40(3): 243-249.
|
| 4 |
Ranzinger J. The receptor for advanced glycation end-products (RAGE) plays a key role in the formation of nanotubes (NTs) between peritoneal mesothelial cells and in murine kidneys [J]. Cell Tissue Res, 2014, 357(3): 667-679.
|
| 5 |
Witowski J, Kawka E, Rudolf A, et al. New developments in peritoneal fibroblast biology: implications for inflammation and fibrosis in peritoneal dialysis [J]. Biomed Res Int, 2015, 1-7.
|
| 6 |
Hu W, Zhang Y, Sigdel KR, et al. The effects of Panax notoginseng saponins on the cytokines and peritoneal function in rats with peritoneal fibrosis [J]. Ren Fail, 2015, 37(9): 1507-1513.
|
| 7 |
Kitamura M. New insights into therapeutic strategies for the treatment of peritoneal fibrosis: learning from histochemical analyses of animal models [J]. Acta Histochem Cytochem, 2014, 47(4): 133-143.
|
| 8 |
Xu T. Impact of rapamycin on peritoneal fibrosis and transport function [J]. Blood Purif, 2012, 34(1): 48-57.
|
| 9 |
Ke C. Aliskiren ameliorates chlorhexidine digluconate-induced peritoneal fibrosis in rats [J]. Eur J Clin Invest, 2010, 40(4): 301-309.
|
| 10 |
杨洪涛. 肾疏宁抑制腹膜透析腹膜纤维化大鼠基质及新生血管的实验研究[J]. 中国中西医结合肾病杂志，2013, 14(3): 294-298.
|
| 11 |
Takakura K. Antiproteinuric effect of pirfenidone in a rat model of anti-glomerular basement membrane glomerulonephritis [J]. Eur J Pharmacol, 2014, 737: 106-116.
|
| 12 |
Silverberg D. Long-term renin-angiotensin blocking therapy in hypertensive patients with normal aorta may attenuate the formation of abdominal aortic aneurysms [J]. J Am Soc Hypertens, 2014, 8(8): 571-577.
|
| 13 |
Huang N. Pharmacokinetics, safety and tolerability of pirfenidone and its major metabolite after single and multiple oral doses in healthy Chinese subjects under Ffd conditions [J]. Drug Res, 2013, 63(8): 388-395.
|
| 14 |
Ji X, Naito Y, Weng H, et al. Renoprotective mechanisms of pirfenidone in hypertension-induced renal injury: through anti-fibrotic and anti-oxidative stress pathways [J]. Biomed Res, 2013, 34(6): 309-319.
|
| 15 |
Navarro-Partida J, Martinez-Rizo AB, Gonzalez-Cuevas J, et al. Pirfenidone restricts Th2 differentiation in vitro and limits Th2 response in experimental liver fibrosis [J]. Eur J Pharmacol, 2012, 678(1-3): 71-77.
|
| 16 |
Wang Y. Pirfenidone attenuates cardiac fibrosis in a mouse model of TAC-induced left ventricular remodeling by suppressing NLRP3 inflammasome formation [J]. Cardiology, 2013, 126(1): 1-11.
|
| 17 |
Schaefer CJ. Antifibrotic activities of pirfenidone in animal models [J]. Eur Respir Rev, 2011, 20(120): 85-97.
|
| 18 |
Chen Z. Involvement of gelsolin in TGF-beta 1 induced epithelial to mesenchymal transition in breast cancer cells [J]. J Biomed Sci, 2015, 22(1): 90.
|
| 19 |
Ziora D. Circulating concentration of markers of angiogenic activity in patients with sarcoidosis and idiopathic pulmonary fibrosis [J]. BMC Pulm Med, 2015, 15(1): 113.
|
| 20 |
Borie R, Quesnel C, Phin S, et al. Detection of alveolar fibrocytes in idiopathic pulmonary fibrosis and systemic sclerosis [J]. PLoS One, 2013, 8(1): 537-536.
|
| 21 |
Hirt-Minkowski P, Marti HP, Hönger G, et al. Correlation of serum and urinary matrix metalloproteases/tissue inhibitors of metalloproteases with subclinical allograft fibrosis in renal transplantation [J]. Transpl Immunol, 2014, 30(1): 1-6.
|
| 22 |
Roche P, Czubryt MP. Pirfenidone and the inflammasome: getting to the heart of cardiac remodeling [J]. Cardiology, 2013, 126(1): 59-61.
|
| 23 |
Shimizu T, Kuroda T, Hata S, et al. Pirfenidone improves renal function and fibrosis in the post-obstructed kidney [J]. Kidney Int, 1998, 54(1): 99-109.
|
| 24 |
Padilla M. Idiopathic pulmonary fibrosis: the role of pathobiology in making a definitive diagnosis [J]. Am J Manag Care, 2015, 21(14): 276-283.
|
| 25 |
Guo L. Hypoxia-Induced Epithelial-Mesenchymal Transition Is Involved in bleomycin-induced lung fibrosis [J]. BioMed Res Int, 2015, 2015: 1-10.
|